Kathryn A. Whitehead

Massachusetts Institute of Technology

Papers

1

Total Citations

200

H-Index

1

About

Kathryn A. Whitehead is a pioneering biomedical engineer whose research lies at the intersection of drug delivery, nanomedicine, and immunology. She is best known for her transformative work in developing lipid nanoparticles (LNPs) for the delivery of nucleic acids, including mRNA and siRNA. Her landmark 2011 study, "Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery," has garnered over 200 citations and introduced a high-throughput, modular approach to nanoparticle design. By synthesizing and evaluating 1,536 structurally distinct nanoparticles, Whitehead’s team uncovered fundamental principles governing cellular uptake and intracellular delivery—insights that have since guided the design of clinically relevant delivery systems. Her contributions have been instrumental in advancing non-viral gene therapies and mRNA vaccines, including technologies that underpin modern COVID-19 vaccines. Recognized with numerous awards, including a National Institutes of Health Director’s New Innovator Award, Whitehead continues to shape the future of precision medicine through her innovative, data-driven approaches to nanocarrier engineering.

Research Focus

Key Achievements

1
H-Index
1
Papers
200
Total Citations
200
Avg Citations/Paper
🏆 Most Cited Paper
Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery
200 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Massachusetts Institute of Technology

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago